DEPDC1基因在上皮性卵巢腫瘤中的表達(dá)及其臨床意義
發(fā)布時間：2018-10-22 14:51
【摘要】：背景:卵巢癌(Ovarian Cancer,OC)在婦科常見三大惡性腫瘤中預(yù)后最差、死亡率最高、五年存活率徘徊在30-40%。上皮性卵巢癌(Epithelial Ovarian Cancer,EOC)又是卵巢惡性腫瘤中最常見的病理類型。CA125、HE4等腫瘤標(biāo)志物結(jié)合經(jīng)陰道超聲檢查等卵巢癌的早期篩查措施已經(jīng)應(yīng)用于臨床多年,但仍有大量卵巢癌患者發(fā)現(xiàn)時已經(jīng)處于晚期。手術(shù)、化療和PARP抑制劑靶向治療是卵巢癌的主要治療手段,CA125、HE4仍是目前確切應(yīng)用于臨床的兩種可以用于監(jiān)測上皮性卵巢癌復(fù)發(fā)和治療效果的生化指標(biāo),盡管其敏感性還遠(yuǎn)不能滿足臨床需求。DEP domain containing 1(DEPDC1)是一個最新發(fā)現(xiàn)的奇特的腫瘤相關(guān)的基因,此基因已證明在人的多種類型的惡性腫瘤中表達(dá)上調(diào)并且與腫瘤分化有關(guān)。DEPDC1是在細(xì)胞周期中能夠調(diào)節(jié)有絲分裂相關(guān)進(jìn)程的基因,從而參與腫瘤的發(fā)生與發(fā)展。目前此基因在卵巢腫瘤中的研究仍為空白。方法:本研究選取自2013年1月到2016年4月在煙臺毓璜頂醫(yī)院婦科住院治療的:47例卵巢惡性腫瘤組織、15例交界性卵巢腫瘤組織、12例卵巢良性腫瘤組織、18例因良性子宮肌瘤手術(shù)的正常卵巢組織,(共計92例)進(jìn)行石蠟包埋切片。所有病例均由青島大學(xué)附屬煙臺毓璜頂醫(yī)院病理科同一組醫(yī)生做出病理診斷,并由組內(nèi)經(jīng)驗(yàn)豐富的病理專家復(fù)片確診。研究檢驗(yàn)DEPDC1基因的表達(dá)主要采取免疫組織化學(xué)染色的方法,并采用Western Blot進(jìn)行蛋白定量驗(yàn)證。結(jié)果:DEPDC1基因在卵巢交界及惡性組(包含交界腫瘤)中的表達(dá)率為98.39%,但在卵巢正常及良性組只有10.00%的DEPDC1高表達(dá)(P0.05)。分析實(shí)驗(yàn)結(jié)果發(fā)現(xiàn)DEPDC1基因在卵巢交界性及惡性腫瘤中高表達(dá),在正常和良性卵巢組織中低表達(dá)。然而DEPDC1基因表達(dá)水平與卵巢上皮性惡性腫瘤的FIGO分期及病理類型并沒有明顯的相關(guān)性。同時,研究發(fā)現(xiàn)CA125水平的升高和DEPDC1基因上調(diào)有一定的相關(guān)性(r=0.393)。結(jié)論:DEPDC1基因在卵巢上皮性惡性腫瘤及交界性卵巢腫瘤中的表達(dá)水平顯著高于正常及良性組織。在今后臨床工作及實(shí)驗(yàn)研究中,DEPDC1基因有望對卵巢上皮性惡性腫瘤的篩查、早期診斷、預(yù)后分析提供有價值的臨床指導(dǎo)。
[Abstract]:Background: ovarian cancer (Ovarian Cancer,OC) has the worst prognosis and the highest mortality among the three common gynecological malignancies, and the five-year survival rate hovers at 30-40. Epithelial ovarian cancer (Epithelial Ovarian Cancer,EOC) is also the most common pathological type of ovarian malignancy. Early screening for ovarian cancer, such as CA125,HE4 and transvaginal ultrasound, has been used in clinical practice for many years. However, there are still a large number of ovarian cancer patients found at the time of late. Surgery, chemotherapy and targeted therapy with PARP inhibitors are the main treatments for ovarian cancer. CA125,HE4 is still the two biochemical markers that can be used to monitor the recurrence and therapeutic effect of epithelial ovarian cancer. Although its sensitivity is far from satisfying clinical needs,. DEP domain containing 1 (DEPDC1) is a novel tumor-related gene, This gene has been proved to be up-regulated and related to tumor differentiation in various types of malignant tumors. DEPDC1 is a gene that regulates mitotic processes in cell cycle and thus participates in the occurrence and development of tumors. At present, the study of this gene in ovarian tumors is still blank. Methods: from January 2013 to April 2016, 47 cases of malignant ovarian tissues, 15 cases of borderline ovarian tumors, 12 cases of benign ovarian tumors and 18 cases of benign ovarian tumors were selected. Paraffin embedded sections were performed in 92 cases of normal ovarian tissue of uterine leiomyoma. All cases were diagnosed by the same group of doctors in the Department of Pathology of Yantai Yuding Hospital affiliated to Qingdao University. The expression of DEPDC1 gene was assayed by immunohistochemical staining and protein quantification by Western Blot. Results: the expression rate of DEPDC1 gene was 98.39% in ovarian borderline and malignant group (including borderline tumor), but only 10.00% of DEPDC1 was overexpressed in normal and benign ovarian group (P0.05). The results showed that DEPDC1 gene was highly expressed in ovarian borderline and malignant tumors, and low in normal and benign ovarian tissues. However, there was no significant correlation between the expression of DEPDC1 gene and the FIGO stage and pathological type of ovarian epithelial tumor. At the same time, there was a correlation between the increase of CA125 level and the up-regulation of DEPDC1 gene (r = 0.393). Conclusion: the expression of DEPDC1 gene in epithelial ovarian neoplasms and borderline ovarian tumors is significantly higher than that in normal and benign tissues. In the future clinical work and experimental research, DEPDC1 gene is expected to provide valuable clinical guidance for screening, early diagnosis and prognostic analysis of ovarian epithelial malignant tumors.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R737.31
本文編號：2287474
[Abstract]:Background: ovarian cancer (Ovarian Cancer,OC) has the worst prognosis and the highest mortality among the three common gynecological malignancies, and the five-year survival rate hovers at 30-40. Epithelial ovarian cancer (Epithelial Ovarian Cancer,EOC) is also the most common pathological type of ovarian malignancy. Early screening for ovarian cancer, such as CA125,HE4 and transvaginal ultrasound, has been used in clinical practice for many years. However, there are still a large number of ovarian cancer patients found at the time of late. Surgery, chemotherapy and targeted therapy with PARP inhibitors are the main treatments for ovarian cancer. CA125,HE4 is still the two biochemical markers that can be used to monitor the recurrence and therapeutic effect of epithelial ovarian cancer. Although its sensitivity is far from satisfying clinical needs,. DEP domain containing 1 (DEPDC1) is a novel tumor-related gene, This gene has been proved to be up-regulated and related to tumor differentiation in various types of malignant tumors. DEPDC1 is a gene that regulates mitotic processes in cell cycle and thus participates in the occurrence and development of tumors. At present, the study of this gene in ovarian tumors is still blank. Methods: from January 2013 to April 2016, 47 cases of malignant ovarian tissues, 15 cases of borderline ovarian tumors, 12 cases of benign ovarian tumors and 18 cases of benign ovarian tumors were selected. Paraffin embedded sections were performed in 92 cases of normal ovarian tissue of uterine leiomyoma. All cases were diagnosed by the same group of doctors in the Department of Pathology of Yantai Yuding Hospital affiliated to Qingdao University. The expression of DEPDC1 gene was assayed by immunohistochemical staining and protein quantification by Western Blot. Results: the expression rate of DEPDC1 gene was 98.39% in ovarian borderline and malignant group (including borderline tumor), but only 10.00% of DEPDC1 was overexpressed in normal and benign ovarian group (P0.05). The results showed that DEPDC1 gene was highly expressed in ovarian borderline and malignant tumors, and low in normal and benign ovarian tissues. However, there was no significant correlation between the expression of DEPDC1 gene and the FIGO stage and pathological type of ovarian epithelial tumor. At the same time, there was a correlation between the increase of CA125 level and the up-regulation of DEPDC1 gene (r = 0.393). Conclusion: the expression of DEPDC1 gene in epithelial ovarian neoplasms and borderline ovarian tumors is significantly higher than that in normal and benign tissues. In the future clinical work and experimental research, DEPDC1 gene is expected to provide valuable clinical guidance for screening, early diagnosis and prognostic analysis of ovarian epithelial malignant tumors.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R737.31
【參考文獻(xiàn)】
相關(guān)期刊論文 前2條
1 李崧;田紅旗;;卵巢癌分子靶向治療研究進(jìn)展[J];中國新藥與臨床雜志;2016年11期
2 盧仁泉;郭林;沈燁紅;;HE4在卵巢癌診治中的臨床應(yīng)用評價[J];中國癌癥雜志;2010年09期
，本文編號：2287474
本文鏈接：http://sikaile.net/kejilunwen/jiyingongcheng/2287474.html
最近更新
教材專著
